OST 246
Alternative Names: OST-246Latest Information Update: 28 Mar 2024
At a glance
- Originator Oncostellae
- Class Anti-inflammatories
- Mechanism of Action Janus kinase 3 inhibitors; Mixed-lineage kinase inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Autoimmune-disorders in Spain (PO)
- 28 Mar 2024 No recent reports of development identified for research development in Inflammation in Spain (PO)
- 27 Feb 2020 Early research in Autoimmune disorders in Spain (PO) before February 2020 (Oncostellae's pipeline, February 2020)